pre-IPO PHARMA

COMPANY OVERVIEW

Sonoma Biotherapeutics is a South San Francisco and Seattle-based company leading the development of adoptive Tregcell therapies for autoimmune and inflammatory diseases. Using genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease-modifying and curative therapies.


LOCATION

  • South San Francisco, CA, USA
  • Seattle, WA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Inflammatory Disease

  • WEBSITE

    https://www.sonomabio.com/


    CAREER WEBSITE

    https://www.sonomabio.com/#careers


    SOCIAL MEDIA


    INVESTORS

    8vc alexandria-venture-investments ally-bridge-group arch-venture-partners arrowmark avidity-partners casdin-capital deep-track-capital fidelity-management-research-company frazier-healthcare-partners gv janus-henderson-investors jdrf-t1d-fund lifeforce-capital lilly-asia-ventures lyell mirae-asset ns-investment octagon osage-university-partners piper-heartland-healthcare-capital vertex-ventures


    PRESS RELEASES


    May 31, 2023

    Page Not Found


    May 31, 2023

    Page Not Found


    Apr 11, 2023

    Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board


    Mar 28, 2023

    Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases


    Nov 10, 2022

    Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022


    For More Press Releases


    Google Analytics Alternative